A5075818619- Osteoarthritis Treatment and Mechanisms
- Inflammatory mediators and NSAID effects
- Rheumatoid Arthritis Research and Therapies
- Pain Mechanisms and Treatments
- Musculoskeletal pain and rehabilitation
- Pharmacological Effects of Natural Compounds
- Health Systems, Economic Evaluations, Quality of Life
- Pain Management and Placebo Effect
- Gastrointestinal motility and disorders
- Biomedical Ethics and Regulation
- Opioid Use Disorder Treatment
- Pain Management and Opioid Use
- Pharmacy and Medical Practices
- Statistical Methods in Clinical Trials
- Migraine and Headache Studies
Pfizer (United Kingdom)
2018-2024
Pfizer (United States)
2021-2022
Napp Pharmaceuticals (United Kingdom)
2015-2016
Therapeutics Clinical Research
2015
Ibero American University
2015
Objective Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in study with 24-week treatment and safety follow-up. Methods This double-blind, randomised, phase III enrolled adults Europe Japan moderate-to-severe OA who had not responded to could tolerate standard-of-care analgesics. Patients were randomised tanezumab 2.5 mg 5 subcutaneously matching placebo every 8 weeks (three doses). Co-primary end points change from baseline week 24...
Objective: Sensory symptom patterns may be useful for predicting treatment response, and, thus, improve individual therapy in patients suffering from neuropathic pain (NeP). Existing screening questionnaires focus predominately on mechanisms without consideration of nociceptive or mixed states. This study aimed to develop a new questionnaire, painPREDICT, using wide set patient-reported descriptors potentially associated with and mechanisms, explore sensory patterns.Methods: PainPREDICT was...
Osteoarthritis (OA) causes substantial pain and reduced health-related quality of life (HRQL). Although opioid analgesics are commonly used, the relative benefits different opioids poorly studied. Transdermal buprenorphine (TDB) offers an alternative to oral for treatment moderate-to-severe chronic pain. This observational study people with OA assessed satisfaction, HRQL medication adherence. Patients in UK self-reported knee and/or hip who had been receiving one or more TDB, co-codamol (an...
To evaluate if early improvements in pain and function with subcutaneous tanezumab are meaningful sustained over 24 weeks.Patients moderate-to-severe osteoarthritis (hip or knee) Europe Japan were randomized to placebo, 2.5 mg 5 (baseline, Week 8 16). Outcomes included: average daily index joint score, Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) subscales, rescue medication use, WOMAC responders (within-patient ≥30% reduction Pain Physical Function), Outcome Measures...
Following marketing authorization in Japan, for almost all new drugs or indications, postmarketing studies (PMS) are a regulatory requirement. These PMS focus on accrual of defined number cases with data being collected predetermined period after approval to confirm efficacy/effectiveness, safety, and quality the Japanese population. In contrast other regions where only required address specific scientific uncertainty, often regardless any therefore, their value is unclear. To determine...
<h3>Background</h3> Tanezumab, a monoclonal antibody against nerve growth factor, is in development for treatment of osteoarthritis (OA) pain. <h3>Objectives</h3> To assess efficacy and safety tanezumab patients with moderate to severe OA pain who have not responded or cannot tolerate standard care analgesics. <h3>Methods</h3> A randomized, double-blind, placebo-controlled study (24 week treatment; 24 follow-up) was conducted Europe Japan the knee hip history insufficient relief intolerance...
Abstract Background Osteoarthritis (OA) causes pain, disability and impaired quality of life. Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the management OA pain. Two randomised, placebo-controlled studies with primary aim assessing efficacy safety subcutaneously administered tanezumab were recently completed as part phase 3 programme, data reported, separately. Here we report pooled analyses secondary outcomes from these two trials: Outcome Measures...